Edgewise Therapeutics, Inc.
NASDAQ:EWTXBiotechnology
+$1.11 today
- Market cap
- $4.45B
- Beta
- 0.30
- P/E (TTM)
- -21.9
- EPS (TTM)
- -$1.64
Volume 0.87M
Average 1.32M
EWTX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Edgewise Therapeutics, Inc.NASDAQ: EWTX
Operating Income · Q3 FY2026 · quarter ended Sep 2026
Operating income remains negative
Q3 FY2026 operating income was -$46.14M, compared with -$46.86M a year earlier. Trailing-twelve-month operating income was -$218.18M.
Context
- Operating income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -20.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$46.14M+25.5% QoQ
- Last fiscal yearDec 2025
- -$191.41M-20.5% YoY
- LTMSep 2026
- -$218.18M-20.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.5% | +100.0% | +98.5 pp |
| 1 year | -20.5% | +100.0% | +120.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (191.41M) USD
- Year-over-year change
- -20.5%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (191.41M) | -20.5% |
| FY2024 | 2024-12-31 | (158.83M) | -38.9% |
| FY2023 | 2023-12-31 | (114.36M) | -59.6% |
| FY2022 | 2022-12-31 | (71.66M) | -65.8% |
| FY2021 | 2021-12-31 | (43.22M) | — |
Operating Income vs competitors
How EWTX compares with its peers on the latest reported figures
- EWTX's LTM Sep 2026 operating income of -$218.18M is the 9th highest of the 10 companies compared; the peer median is -$172.43M.
- Its year-over-year change of -20.6% is the 3rd highest of 10, against a peer median of -63.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $116.26M | -83.8% | — | 11.5% | |
| LTM Mar 2026 | -$40.96M | +65.1% | — | 1.9% | |
| LTM Mar 2026 | -$81.23M | +25.7% | — | — | |
| LTM Mar 2026 | -$119.93M | -109.4% | — | — | |
| LTM Mar 2026 | -$172.43M | -63.7% | — | — | |
| LTM Mar 2026 | -$178.41M | -4443.0% | — | 3109.3% | |
| LTM Mar 2026 | -$185.25M | -584.4% | — | 577.5% | |
| LTM Mar 2026 | -$196.46M | -37.5% | — | — | |
| LTM Sep 2026 | -$218.18M | -20.6% | — | — | |
| LTM Jun 2026 | -$536.96M | -21.8% | — | — | |
| Peer median (excluding EWTX) | -$172.43M | -63.7% | — | 294.5% | |
Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.27M |
| Gross Profit | 0 | 0 | 0 | 0 | (2.27M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.19M | 54.03M | 90.91M | 126.97M | 151.39M |
| Selling, General & Admin | 11.03M | 17.63M | 23.45M | 31.87M | 40.02M |
| Operating Expenses | 43.22M | 71.66M | 114.36M | 158.83M | 189.14M |
| Depreciation & Amortization | 272K | 538K | 1.73M | 2.29M | 2.27M |
| EBITDA | (42.54M) | (63.08M) | (98.43M) | (131.52M) | (165.53M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.22M) | (71.66M) | (114.36M) | (158.83M) | (191.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 402K | 2.66M | 14.19M | 25.02M | 23.61M |
| Interest Expense | 0 | 4.02M | 0 | 0 | 0 |
| Other Income / Expenses | 402K | 4.02M | 14.19M | 25.02M | 23.61M |
| Income Before Tax | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.86) | (1.26) | (1.57) | (1.45) | (1.63) |
| EPS (Diluted) | (0.86) | (1.26) | (1.57) | (1.45) | (1.63) |
| Weighted Avg Shares | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M |
| Weighted Avg Shares (Diluted) | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M |
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
Intrinsic Alpha fair value
Locked
Current Price
$41.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.